HC Wainwright & Co. Downgrades Kinnate Biopharma to Neutral
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has downgraded Kinnate Biopharma from Buy to Neutral.
September 19, 2023 | 10:07 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kinnate Biopharma has been downgraded from Buy to Neutral by HC Wainwright & Co.
The downgrade from Buy to Neutral by a reputable analyst could potentially lead to a decrease in the stock price of Kinnate Biopharma in the short term as it may influence investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100